Last reviewed · How we verify

Sofosbuvir + Simeprevir — Competitive Intelligence Brief

Sofosbuvir + Simeprevir (Sofosbuvir + Simeprevir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor). Area: Virology/Hepatology.

marketed Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor) HCV NS5B polymerase and NS3/4A protease Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Sofosbuvir + Simeprevir (Sofosbuvir + Simeprevir) — University of California, San Francisco. Sofosbuvir and simeprevir work together to inhibit hepatitis C virus replication by blocking the NS5B polymerase and NS3 protease, respectively.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sofosbuvir + Simeprevir TARGET Sofosbuvir + Simeprevir University of California, San Francisco marketed Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor) HCV NS5B polymerase and NS3/4A protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor) class)

  1. University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofosbuvir + Simeprevir — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-simeprevir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: